BPCR Insider Trading

Insider Ownership Percentage: 7.68%
Insider Buying (Last 12 Months): £63,171.74
Insider Selling (Last 12 Months): GBX 0

BioPharma Credit Insider Trading History Chart

This chart shows the insider buying and selling history at BioPharma Credit by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioPharma Credit Share Price & Price History

Current Price: GBX 0.96
Price Change: +0.30 (1.20%)
As of 03/31/2023 01:00 AM ET

This chart shows the closing price history over time for BPCR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BioPharma Credit Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/27/2023Sapna ShahInsiderBuy22,342GBX 97£21,671.74
10/24/2022Rolf SoderstromInsiderBuy50,000GBX 83£41,500
9/30/2020Rolf SoderstromInsiderBuy50,000GBX 79£39,500
See Full Table

SEC Filings (Institutional Ownership Changes) for BioPharma Credit (LON:BPCR)

39.24% of BioPharma Credit stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

BioPharma Credit logo
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.
Read More on BioPharma Credit

Today's Range

Now: GBX 0.96
Low: 0.95
High: 0.97

50 Day Range

MA: GBX 0.96
Low: 0.95
High: 0.97

52 Week Range

Now: GBX 0.96
Low: 0.89
High: 1.05


1,226,918 shs

Average Volume

1,049,049 shs

Market Capitalization

£12.62 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of BioPharma Credit?

BioPharma Credit's top insider investors include:
  1. Rolf Soderstrom (Insider)
  2. Sapna Shah (Insider)
Learn More about top insider investors at BioPharma Credit.